Human Molecular Genetics Advance Access originally published online on August 12, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Human Molecular Genetics, 2003, Vol. 12, Review Issue 2 R259-R264
DOI: 10.1093/hmg/ddg272
© 2003 Oxford University Press
Glycosylation defects: a new mechanism for muscular dystrophy?
Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham, UK
Received July 2, 2003; Accepted July 18, 2003
Recently, post-translational modification of proteins has been defined as a new area of focus for muscular dystrophy research by the identification of a group of disease genes that encode known or putative glycosylation enzymes. Walker–Warburg Syndrome (WWS) and muscle–eye–brain disease (MEB) are caused by mutations in two genes involved in O-mannosylation, POMT1 and POMGnT1, respectively. Fukuyama muscular dystrophy (FCMD) is due to mutations in fukutin, a putative phospholigand transferase. Congenital muscular dystrophy type 1C and limb girdle muscular dystrophy type 2I are allelic, both being due to mutations in the gene-encoding fukutin-related protein (FKRP). Finally, the causative gene in the myodystrophy (myd) mouse is a putative bifunctional glycosyltransferase (Large). WWS, MEB, FCMD and the myd mouse are also associated with neuronal migration abnormalities (often type II lissencephaly) and ocular or retinal defects. A deficiency in post-translational modification of 
-dystroglycan is a common feature of all these muscular dystrophies and is thought to involve O-glycosylation pathways. This abnormally modified -dystroglycan is deficient in binding to extracellular matrix ligands, including laminin and agrin. Selective deletion of dystroglycan in the central nervous system (CNS) produces brain abnormalities with striking similarities to WWS, MEB, FCMD and the myd mouse. Thus, impaired dystroglycan function is strongly implicated in these diseases. However, it is unlikely that these five glycosylation enzymes only have a role in glycosylation of -dystroglycan and it is important that other protein targets are identified.
* To whom correspondence should be addressed at: Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK. Tel: +44 1158493229; Fax: +44 1159709906; Email: jane.hewitt{at}nottingham.ac.uk
Present address: Department of Cellular and Molecular Medicine, Howard Hughes Medical Institute, University of California San Diego, California 92093, USA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Masuda-Hirata, A. Suzuki, Y. Amano, K. Yamashita, M. Ide, T. Yamanaka, M. Sakai, M. Imamura, and S. Ohno Intracellular polarity protein PAR-1 regulates extracellular laminin assembly by regulating the dystroglycan complex Genes Cells, July 1, 2009; 14(7): 835 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Alavi and J. S. Axford Sweet and sour: the impact of sugars on disease Rheumatology, June 1, 2008; 47(6): 760 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. P. Wairkar, L. G. Fradkin, J. N. Noordermeer, and A. DiAntonio Synaptic Defects in a Drosophila Model of Congenital Muscular Dystrophy J. Neurosci., April 2, 2008; 28(14): 3781 - 3789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Sher, C. Aoyama, K. A. Huebsch, S. Ji, J. Kerner, Y. Yang, W. N. Frankel, C. L. Hoppel, P. A. Wood, D. E. Vance, et al. A Rostrocaudal Muscular Dystrophy Caused by a Defect in Choline Kinase Beta, the First Enzyme in Phosphatidylcholine Biosynthesis J. Biol. Chem., February 24, 2006; 281(8): 4938 - 4948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J van Reeuwijk, M Janssen, C van den Elzen, D Beltran-Valero de Bernabe, P Sabatelli, L Merlini, M Boon, H Scheffer, M Brockington, F Muntoni, et al. POMT2 mutations cause {alpha}-dystroglycan hypoglycosylation and Walker-Warburg syndrome J. Med. Genet., December 1, 2005; 42(12): 907 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kunz, J. M. Rojek, M. Kanagawa, C. F. Spiropoulou, R. Barresi, K. P. Campbell, and M. B. A. Oldstone Posttranslational Modification of {alpha}-Dystroglycan, the Cellular Receptor for Arenaviruses, by the Glycosyltransferase LARGE Is Critical for Virus Binding J. Virol., November 15, 2005; 79(22): 14282 - 14296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Grewal, J. M. McLaughlan, C. J. Moore, C. A. Browning, and J. E. Hewitt Characterization of the LARGE family of putative glycosyltransferases associated with dystroglycanopathies Glycobiology, October 1, 2005; 15(10): 912 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Huang, J. Sylvan, M. Jonas, R. Barresi, P. T. C. So, K. P. Campbell, and R. T. Lee Cell stiffness and receptors: evidence for cytoskeletal subnetworks Am J Physiol Cell Physiol, January 1, 2005; 288(1): C72 - C80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Connors, M. E. Adams, S. C. Froehner, and P. Kofuji The Potassium Channel Kir4.1 Associates with the Dystrophin-Glycoprotein Complex via {alpha}-Syntrophin in Glia J. Biol. Chem., July 2, 2004; 279(27): 28387 - 28392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sahashi, T. Ibi, K. Ohno, K. Sahashi, N. Nakao, and H. Kondo Progressive myopathy with circulating autoantibody against giantin in the Golgi apparatus Neurology, May 25, 2004; 62(10): 1891 - 1893. [Abstract] [Full Text] [PDF]
|
|